Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InnoCare Pharma Ltd. ( (HK:9969) ) has shared an update.
InnoCare Pharma Limited, a biopharmaceutical group incorporated in the Cayman Islands and listed in Hong Kong and on Shanghai’s STAR Market, focuses on innovative drug development and commercialization in China’s healthcare sector. The company leverages equity fundraising to support research, development and broader growth initiatives across its subsidiaries.
The company announced an update to the use of unutilized net proceeds from its 2022 RMB share issue on the STAR Market, which raised approximately RMB2.78 billion after expenses. The board approved internal adjustments to the investment structure within the originally disclosed categories, stating that the total committed amount remains unchanged and that the revised allocation will not alter the intended uses of funds, while allowing flexibility to respond to market conditions and pursue better business performance.
In its statement, InnoCare emphasized that the updated deployment of idle proceeds is consistent with the development direction outlined in prior shareholder circulars. The board indicated it will continue to review and, if necessary, further revise the plan for remaining unutilized proceeds to optimize capital efficiency and support the group’s operational and strategic objectives.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong and Shanghai that focuses on discovering, developing and commercializing innovative therapies. The group operates through subsidiaries and is positioning itself in China’s capital markets to support long-term research and development and business expansion in the healthcare sector.
The company has previously raised funds through an RMB share issue on the STAR Market, generating net proceeds of about RMB2.78 billion after issuance expenses. Its board and management structure include executive, non-executive and independent non-executive directors overseeing strategic and capital allocation decisions.
Average Trading Volume: 6,876,447
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.58B
Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.